Figure 3
Fibroblast growth factor 2-targeted Ad-NBS1 gene transfer sensitizes head and neck cancer with cisplatin-based chemotherapy in vitro and in vivo. Tumour cell growth curve analysis in vitro at an MOI of 5 (A) and 10 (B) in six different treatment groups. Fibroblast growth factor 2-targeted Ad-NBS1 with cisplatin group had the greatest tumour suppression effect at an MOI of 5 (A), whereas no difference was observed between FGF2-Ad-NBS1/Cisplatin and Ad-NBS1/Cisplatin at an MOI of 10 (B). The FGF2-targeted system might enable a lower titre administration. Tumour volume changes before and after treatments are shown in the mouse model. (C) The greatest tumour shrinkage occurred when Ad-NBS1 gene therapy was combined with Regular cisplatin. The tumour treated with Ad-NBS1/Reduced cisplatin also showed better a tumour suppression effect when compared with the regular dose of cisplatin-treated tumours. (D) The combination Ad-NBS1/Regular cisplatin and FGF2-Ad-NBS1/Reduced cisplatin had the greatest efficacy in reducing tumour size and the effect was almost the same in both treatments. Fibroblast growth factor 2-Ad-NBS1 therapy enhances sensitivity for cisplatin intensely and allows for reduction of cisplatin dose. #P<0.01 when compared with Ad-NBS1/Regular dose of cisplatin, ##P<0.05 when compared with Ad-NBS1/Regular dose of cisplatin, +P<0.01 when compared with Ad-NBS1/Reduced dose of cisplatin, ++P<0.05 when compared with Ad-NBS1/Reduced dose of cisplatin, *P<0.01 when compared with FGF2-Ad-NBS1/Reduced dose of cisplatin, **P<0.05 when compared with FGF2-Ad-NBS1/Reduced dose of cisplatin.
